Aprepitant can increase the levels of the
ergot derivatives in the short-term, then reduce them within 2 weeks. Ergotism could occur. Fosaprepitant, a prodrug of
aprepitant, would be expected to interact similarly.
The effect may persist for 2 weeks after
aprepitant is stopped. Avoid the combination where possible. Concurrent use needs close monitoring.